BPC-157 Research Guide

01 What Is BPC-157?

BPC-157, formally Body Protection Compound 157, is a synthetic pentadecapeptide (15 amino acids) first isolated from the sequence of human gastric juice protein BPC. Unlike many research peptides, BPC-157 is notable for its exceptional stability — it remains active across a wide pH range and resists enzymatic degradation in the gut, which explains why oral administration produces measurable systemic effects in rodent gavage models.

Researchers at the University of Zagreb, led by Dr. Predrag Sikiric, have published over 100 peer-reviewed papers on BPC-157 since the 1990s, making it one of the most studied cytoprotective peptides in preclinical literature. The compound's broad activity profile — spanning GI protection, tendon/muscle healing, CNS modulation, and cardiovascular effects — stems from its interaction with multiple signalling pathways rather than a single receptor.

02 Mechanism of Action

BPC-157's broad cytoprotective effects appear to stem from its interaction with several interconnected signalling systems:

Nitric Oxide (NO) System Modulation

BPC-157 upregulates eNOS (endothelial nitric oxide synthase) expression and rescues NO production in damaged endothelium. Studies in rat models of NSAID-induced gastric lesions demonstrated that BPC-157 reversed endothelial dysfunction by restoring NO signalling, which in turn promoted angiogenesis and mucosal restitution.

Growth Factor Upregulation

BPC-157 has been shown to upregulate VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor) receptor expression in fibroblasts and tendon cells. This angiogenic and proliferative signalling accounts for the accelerated wound closure and tendon-to-bone integration observed in surgical models.

FAK & Paxillin Pathway

In fibroblast migration studies, BPC-157 activated focal adhesion kinase (FAK) and paxillin phosphorylation, accelerating cell migration into wound sites. This mechanism is distinct from and complementary to growth factor signalling.

Dopamine & Serotonin Modulation

CNS studies have documented BPC-157's ability to modulate dopaminergic and serotonergic tone. In dopamine system overdose models, BPC-157 counteracted dyskinesia and catalepsy, suggesting receptor-level interactions not yet fully characterised.

03 Musculoskeletal Research

The musculoskeletal application of BPC-157 has been the most actively studied domain, yielding consistently positive results across tendon, muscle, ligament, and bone models.

Tendon Healing

In a widely cited Achilles tendon transection model (rats), BPC-157 administered SC at 10 µg/kg accelerated tendon-to-bone reattachment by 40% compared to controls, with histological evidence of improved collagen organisation and vascularisation at 2 and 4 weeks post-injury.

Muscle Injury & Repair

Crush injury models demonstrated BPC-157's ability to accelerate functional recovery of gastrocnemius muscle. Grip strength measurements returned to baseline 30% faster in treated animals, correlated with reduced inflammatory infiltrate and earlier satellite cell activation.

Ligament & Bone

Medial collateral ligament (MCL) transection studies showed BPC-157-treated animals had superior biomechanical properties at 4 weeks. Bone defect models in rabbits demonstrated enhanced osteoblast activity and earlier cortical bridging.

04 Gastrointestinal Studies

BPC-157 was originally characterised as a cytoprotective gastric peptide, and GI research remains its strongest evidence base. It has demonstrated protective and therapeutic effects across a wide range of GI injury models.

NSAID-Induced Gastropathy

In aspirin and indomethacin-induced gastric ulcer models, both oral and IP administration of BPC-157 dramatically reduced ulcer index scores. Notably, oral doses as low as 10 ng/kg showed protective effects — an unusually low threshold suggesting high intrinsic potency.

Inflammatory Bowel Disease Models

In TNBS- and DSS-induced colitis models, BPC-157 reduced macroscopic and microscopic damage scores, reduced myeloperoxidase activity, and normalised mucosal architecture. Intraluminal application was as effective as systemic injection in some models.

Oesophageal & Fistula Healing

Oesophago-gastric anastomosis leak models showed BPC-157 reduced anastomotic failure rate and accelerated fistula closure — results that have drawn interest from surgical research communities.

05 CNS & Neuroprotection

BPC-157's effects on the nervous system represent one of its most intriguing but mechanistically complex research areas.

Traumatic Brain Injury Models

Rodent models of focal cortical injury showed BPC-157 IP administration reduced lesion volume, improved motor function scores, and attenuated oxidative stress markers. Effects persisted at 4 weeks with both early and delayed dosing protocols.

Peripheral Nerve Repair

Sciatic nerve crush and transection studies documented accelerated axonal regeneration and faster functional recovery in treated animals. BPC-157 upregulated GAP-43 (growth-associated protein), a marker of active axonal sprouting.

Monoamine System Interactions

Extensive pharmacological challenge studies have shown BPC-157 counteracts both dopamine agonism (amphetamine-induced hyperlocomotion) and antagonism (haloperidol-induced catalepsy), suggesting it acts as a modulator of dopaminergic tone rather than a direct agonist or antagonist.

Depression & Anxiety Models

Forced swim test and open field test results in rodents suggest anxiolytic and antidepressant-like effects, associated with modulation of HPA axis markers and normalisation of CRH signalling.

06 Cardiovascular Findings

The cardiovascular research on BPC-157 is primarily centred on its angiogenic and endothelial-protective properties. In rat models of surgically induced heart failure, BPC-157 preserved cardiac function markers and attenuated myocardial fibrosis. Aortic NO synthase expression was significantly higher in treated animals, consistent with the compound's established role in endothelial NO restoration.

Thrombus formation studies showed BPC-157 shortened time-to-thrombus and paradoxically accelerated vessel wall repair post-thrombosis — findings attributed to its dual role in promoting fibrinolysis and angiogenic restitution of the vessel wall.

07 Comparison: BPC-157 vs Related Peptides

08 Protocol Notes (Preclinical)

Dosing Observed in Rodent Studies

• Low dose range: 10 ng/kg – 10 µg/kg (GI models)
• Mid dose range: 1–10 µg/kg (musculoskeletal, CNS models)
• High dose range: 100 µg/kg (acute injury models)

Administration Routes

• Subcutaneous (SC): Most common systemic route; daily or every-other-day dosing
• Intraperitoneal (IP): Used for acute pharmacological studies
• Intragastric (oral gavage): Demonstrates oral bioavailability; used for GI and systemic endpoints
• Local injection: Into tendon/ligament tissue in surgical models

Reconstitution

BPC-157 lyophilised powder is typically reconstituted in bacteriostatic water or sterile saline. Reconstituted solutions should be stored at 4°C (short-term) or −20°C (longer-term) and used within 30 days. Avoid repeated freeze-thaw cycles.

09 Safety Profile (Preclinical)

BPC-157 has an unusually clean preclinical safety profile across hundreds of published studies:

• No LD50 established — doses up to 100 mg/kg IP in rodents did not produce mortality
• No oncogenic risk identified — several studies tested tumour models; BPC-157 did not accelerate tumour growth
• No hormonal disruption — no effects on pituitary hormones, sex steroids, or thyroid function in chronic dosing studies
• No hepatotoxicity or nephrotoxicity in standard organ function panels

10 Frequently Asked Questions